Jazz Pharmaceuticals Plc Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
A Quick Look at Today's Ratings for Jazz Pharmaceuticals(JAZZ.US), With a Forecast Between $147 to $220
Optimistic Buy Rating for Jazz Pharmaceuticals Amidst Short-term Challenges and Long-term Growth Potential
Jazz Pharmaceuticals Balances Growth and Challenges in Earnings Call
Top Gap Ups and Downs on Wednesday: BABA, DIS, MRVL and More
Express News | Baird Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $155
RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $172
Jazz Pharmaceuticals Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results and Cut Its FY25 Adjusted EPS Guidance. Also, Piper Sandler and Morgan Stanley Lowered Their Respective Price Targets on the Stock.
Express News | Jazz Pharmaceuticals Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results and Cut Its FY25 Adjusted EPS Guidance. Also, Piper Sandler and Morgan Stanley Lowered Their Respective Price Targets on the Stock
Express News | Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Lowers Price Target to $166
A Quick Look at Today's Ratings for Jazz Pharmaceuticals(JAZZ.US), With a Forecast Between $166 to $216
Express News | Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $200 Price Target
Jazz Pharmaceuticals Analyst Ratings
Analysts Conflicted on These Healthcare Names: Spyre Therapeutics (SYRE), Fresenius Medical Care (FMS) and Jazz Pharmaceuticals (JAZZ)
Jazz Pharmaceuticals | 10-Q: Q1 2025 Earnings Report
Piper Sandler Sticks to Their Buy Rating for Jazz Pharmaceuticals (JAZZ)
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Vera Therapeutics (VERA) and Dexcom (DXCM)
Earnings Call Summary | Jazz Pharmaceuticals(JAZZ.US) Q1 2025 Earnings Conference
Jazz Outlines $4.15B-$4.4B Revenue Target for 2025 Amid Growth in Neuroscience Portfolio and New Oncology Approvals
Express News | Jazz Pharmaceuticals PLC : Piper Sandler Cuts Target Price to $147 From $176